Clinical trials: Thrombin

Thrombin Inhibition

Oral AZD8165 After Single Oral Ascending Doses in Healthy Male Subjects

• Terminated
• Age: 18 to 45 years
• Phase 1
• Pill or oral medicine

The purpose of this study is to evaluate the safety and tolerability of AZD8165 and the pharmacokinetics of the metabolite AZ12971554 and plasma levels of the prodrug AZD8165 after escalating single oral low doses.

Trial name

NCT01150812

Testing

AZD8165

Where

United States

Volunteers

9 people, healthy volunteers welcome

Sponsor

AstraZeneca